November 9, 2022
The key objectives include the assessment of the efficacy and safety of OQL011 and the identification of an optimal dosage for Phase III.
Targeted oncology supportive therapy company OnQuality Pharmaceuticals has enrolled the first participant in Part 2 of the NOVA-II Phase II clinical trial of OQL011 to manage Hand-Foot Skin Reaction (HFSR) in cancer patients.
The topical ointment will be evaluated in the patients who are receiving vascular endothelial growth factor receptor inhibitor(s) (VEGFRi) as part of their treatment.
The international multicentre, double-blinded, randomised, vehicle-controlled, dose-ranging trial will evaluate OQL011’s safety and efficacy as a topical ointment to treat VEGFR inhibitor-associated HFSR.
Read the full article here: https://www.clinicaltrialsarena.com/news/onquality-first-subject-hfsr-therapy/